Cytokine gene expression in regenerating haematopoietic tissues of mice after cyclophosphamide treatment

Acta Haematologica

Volumn 109, Issue 2, 2003, Pages 68-75

  Pšenák, Oskar ^a   Sefc L ^a   Sykora V ^a   Chang, K T ^a   Necas E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cyclophosphamide; Cytokines; Gene expression; Haematopoietic progenitor cells; Real time RT PCR

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; ONCOSTATIN M; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL CYCLE; CELL DAMAGE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; STEM CELL MOBILIZATION; TISSUE REGENERATION;

ANIMALS; BONE MARROW; CHEMOKINES, CXC; CYCLOPHOSPHAMIDE; CYTOKINES; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; ONCOSTATIN M; PEPTIDES; REGENERATION; RNA, MESSENGER; SPLEEN; STEM CELL FACTOR; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037219655     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068490     Document Type: Article

References (29)

1. McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991;19:226-231.
2. Heinrich MC, Dooley DC, Freed AC, Band L, Hoatlin ME, Keeble WW, Peters ST, Silvey KV, Ey FS, Kabat D: Constitutive expression of steel factor gene by human stromal cells. Blood 1993;82:771-783.
3. Toksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV, Martin FH, Williams DA: Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 1992;89:7350-7354.
4. Okomura N, Tsuji K, Ebihara Y, Tanaka I, Sawai N, Koike K, Komiyama A, Nakahata T: Chemotactic and chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells. Blood 1996;87:4100-4108.
5. Kim CH, Broxmeyer HE: In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: Stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998;91:100-110.
6. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M: Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996;88:429-436.
7. Graham GJ, Wright EG, Hewick SD, Wolpe SD, Wilkie NM, Donaldson D, Lorimore S, Pragnell IB: Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature 1990;344:442-444.
8. Jacobsen SE, Ruscetti FW, Ortiz M, Gooya JM, Keller JR: The growth response of Lin-Thy-1+ hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors. Exp Hematol 1994;22:985-989.
9. Jacobsen SE, Veiby OP, Myklebust J, Okkenhaug C, Lyman SD: Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha. Blood 1996;87:5016-5026.
10. Kohn FR, Landkamer GJ, Sladek NE: Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557). Immunopharmacol Immunotoxicol 1987;9:163-176.
11. Hatzfeld J, Li ML, Brown EL, Sookdeo H, Levesque JP, O'Toole T, Gurney C, Clark SC, Hatzfeld A: Release of early human hematopoietic progenitors from quiescence by anti-sense transforming growth factor beta 1 or Rb oligonucleotides. J Exp Med 1991;174:925-929.
12. Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, Le Bousse-Kerdiles MC: Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: Possible role in progenitor survival. Blood 2000;95:756-768.
13. Brown TJ, Liu J, Brashem-Stein C, Shoyab M: Regulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor expression by oncostatin M. Blood 1993;82:33-37.
14. Wallace PM, MacMaster JF, Rillema JR, Peng J, Burstein SA, Shoyab M: Thrombocytopoietic properties of oncostatin M. Blood 1995;86:1310-1315.
15. Clegg CH, Rulffes JT, Wallace PM, Haugen HS: Regulation of an extrathymic T-cell development pathway by oncostatin M. Nature 1996;384:261-263.
16. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD: Hematologic effects of flt3 ligand in vivo in mice. Blood 1996;88:2004-2012.
17. Liu F, Poursine-Laurent J, Link DC: The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt3 ligand. Blood 1997;90:2522-2528.
18. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
19. Šefc L, Pšenák O, Sýkora V, Nečas E: SDF-1 and its receptor CXCR-4 mRNA in murine hematopoietic tissues during increased migration of progenitors between bone marrow and spleen. Exp Hematol 2001;29(suppl 1):79.
20. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T: Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000;106:1331-1339.
21. Ghaffar A, Sigel MM, Huggins EM Jr: Resistance of helper T lymphocytes to cyclophosphamide. Int J Immunopharmacol 1985;7:449-454.
22. Peterson VM, Adamovicz JJ, Elliott TB, Moore MM, Madonna GS, Jackson WE 3rd, Ledney GD, Gause WC: Gene expression of hematoregulatory cytokines is elevated endogenously after sublethal gamma irradiation and is differentially enhanced by therapeutic administration of biologic response modifiers. J Immunol 1994;153:2321-2330.
23. Orazi A, Gordon MS, John K, Sledge G Jr, Neiman RS, Hoffman R: In vivo effects of recombinant human stem cell factor treatment. A morphologic and immunohistochemical study of bone marrow biopsies. Am J Clin Pathol 1995;103:177-184.
24. Šefc L, Pšenák O, Sýkora V, Šulc K, Nečas E: Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen. J Hematother Stem Cell Res, in press.
25. Nikcevich AD, Young MR, Ellis NK, Newby M, Wepsic HT: Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis. J Immunopharmacol 1986;8:299-313.
26. Rowley SD, Brashem-Stein C, Andrews R, Bernstein ID: Hematopoietic precursors resistant to treatment with 4-hydroperoxycyclophosphamide: Requirement for an interaction with marrow stroma in addition to hematopoietic growth factors for maximal generation of colony-forming activity. Blood 1993;82:60-65.
27. Lyman SD, James L, Bos TV, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR: Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 1993;75:1157-1167.
28. Minehata K, Sekine K, Hara T, Donovan P, Hirabayashi Y, Inoue T, Miyajima A: A role for oncostatin M in the bone marrow hematopoietic microenvironment. Exp Hematol 2001;29(suppl 1):101.
29. Byfield JE, Calabro-Jones PM: Resistance of human T-CFUcs to activated cyclophosphamide: A feature common with critical marrow stem cells? Br J Cancer 1985;52:403-405.